UK markets closed

Santhera Pharmaceuticals Holding AG (SPHDF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
1.41000.0000 (0.00%)
As of 03:28PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close1.4100
Open1.4100
Bid0.0000 x 0
Ask0.0000 x 0
Day's range1.4100 - 1.4100
52-week range1.3700 - 3.0500
Volume500
Avg. volume0
Market cap69.919M
Beta (5Y monthly)1.09
PE ratio (TTM)N/A
EPS (TTM)-1.6800
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Santhera Updates on Ongoing NDA Submission for Vamorolone

    Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, June 29, 2022 – Santhera Pharmaceuticals (SIX: SANN) announces that the clinical module of its rolling new drug application (NDA) for vamorolone in Duchenne muscular dystrophy (DMD) has been submitted to the U.S. Food and Drug Administration (FDA). Finalization of the NDA submission to start the FDA official review is postponed by 4-6 months to Q4-2022 after a third-party contract manufacturing organization (CMO) communicated a de

  • Globe Newswire

    Santhera Nominates Thomas Meier, PhD, to Succeed Elmar Schnee as Chairman of the Board

    Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, June 27, 2022 -- Santhera Pharmaceuticals (SIX: SANN) announces that Chairman of the Board Elmar Schnee will not stand for re-election at the upcoming Annual General Meeting on June 30, 2022. The Board of Directors has unanimously nominated Thomas Meier, PhD, for election as Chairman of the Board and as member of the Compensation Committee. Elmar Schnee, Chairman of the Board and member of the Compensation Committee of Santhera si

  • Globe Newswire

    Santhera Reports 2021 Annual Results

    Ad hoc announcement pursuant to Art. 53 LR A conference call will be held today at 14:30 CEST, 13:30 BST, 08:30 EDT. Details are at the end of this statement. Revenue from contracts with customers of CHF -1.6 million (2020: CHF 15.0 million)Operating result of CHF -56.9 million (2020: CHF -53.1 million) and net result of CHF -55.5 million (2020: CHF -67.7 million)Cash and cash equivalents of CHF 21.2 million as of December 31, 2021Recent financing is expected to provide funding through Q1-2023 o